with MIMETAS using innovative assays.
We are thrilled to share this significant advancement in predictive gastrointestinal toxicity research, in collaboration with MIMETAS. This study highlights how the OrganoReady® Colon Organoid, combined with our CellTiter-Glo® 3D Cell Viability Assay, LDH-Glo™ Cytotoxicity Assay, and P450-Glo™ CYP3A4 Assay, addresses a critical need in drug development by predicting unwanted gastrointestinal effects.
